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2018 Cell Culture Engineering Award Winner 
William M. Miller 
Northwestern University 
Bill has served the cell culture community for 30+ years through pioneering 
contributions, leadership, and training. Common themes in his research are (1) 
cell plasticity and the importance of the culture environment for modulating 
cell responses and (2) taking inspiration from the in vivo environment to 
develop more effective culture systems for cell-based therapies and tissue 
engineering. Bill’s most significant contributions include: 
 Biotherapeutic protein production: Bill’s PhD and independent research played a leading role in 
exploring environmental effects on cell growth, metabolism, and protein production, and helped 
provide the foundation for efficient biotherapeutic protein production. His papers on dilution rate, 
pH, and the levels of nutrients and metabolic byproducts have been highly cited and generated 
substantial interest in the biotechnology industry. Subsequent research elucidated the 
mechanisms responsible for cell inhibition by elevated pCO2. 
 Blood stem cells and megakaryocytes: Bill and collaborator Terry Papoutsakis were the first to 
show that low pO2 greatly enhanced stem and progenitor cell expansion, which has since been 
reported for a wide variety of stem cells. They developed mathematical models of the bone 
marrow O2 distribution and confirmed that stem and primitive progenitor cells likely reside at low 
pO2 in vivo. Bill’s team discovered that 
differentiation of megakaryocytic and 
erythroid cells, which must reach the bone 
marrow sinuses before they fully mature into 
non-motile platelets and red blood cells, is 
greatly enhanced at higher pO2 and pH. These 
findings facilitated development of an 
efficient multi-stage culture process for 
megakaryocytic cells and platelets.  
 Bioreactors for blood cells and tissue engineering:  Bill and collaborators were among the first to 
develop bioreactors for blood stem and progenitor cells. They demonstrated the benefits of 
continuous perfusion for progenitor cell expansion, and showed that blood cells could be more 
effectively cultured in controlled, stirred-tank suspension bioreactors than in static flasks. More 
recently, Bill’s team used computational fluid dynamics to design a uniform-shear-rate 
microbioreactor to study platelet production, and developed well-characterized and controlled 
bioreactors to support renal cell expansion and differentiation in decellularized kidney scaffolds.  
 Mentorship and Service: Bill has directed Northwestern’s MS in Biotechnology Program for 10 
years, directed the NIH Predoctoral Biotechnology Training Program since 2014, and co-directed a 
postdoctoral NIH training program at the intersection of engineering/data science and pediatrics 
since 2015. He has trained 39 PhD students, 7 postdoctoral fellows, and many MS and 
undergraduate students. His former trainees work and play leadership roles in a wide range of 
(bio)pharmaceutical and biotechnology companies.  He has also been an active member of the 
cell culture engineering community, having chaired CCE VII with Richard Schoenfeld in Santa Fe, 
NM and the Scale-up and Manufacturing of Cell-Based Therapies V conference with Tom Brieva. 
This prestigious award recognizes outstanding contributions to the field of Cell Culture and is given bi-
annually at the Cell Culture Engineering conference. Former recipients: Wei-Shou Hu (2002), Eleftherios 
T. Papoutsakis (2004), W. Robert Arathoon (2006), Martin Fussenegger (2008), Michael J. Betenbaugh 
(2010), James M. Piret (2012), Jeffrey J. Chalmers (2014), and Konstantin B. Konstantinov (2016). 
2018 Martin Sinacore Young Investigator Award Winner 
 
Amanda M. Lewis 
Bristol-Myers Squibb 
 
Amanda Lewis is a Senior Engineer in Manufacturing Sciences & Technology at Bristol-Myers Squibb, where 
she leads a team of scientists and engineers responsible for supporting new and existing commercial biologics 
processes.  She first joined BMS in 2013 in Biologics Development, and since then has held positions with 
increasing levels of responsibility.  In her time at BMS, she has developed expertise in ‘Omics tools for 
monitoring and characterization of biologics processes, and has led several studies using metabolomics and 
transcriptomics to increase understanding and control of product glycosylation.  She currently leads a cross-
functional and cross-site initiative to integrate metabolomics testing into commercial programs to increase 
process understanding and robustness.  She also leads a white paper exercise to understand key relationships 
between critical quality attributes and process control from an end to end biologics design, development, and 
commercialization perspective.  She received her B.S. from MIT in 2008, and her PhD from the University of 
Texas at Austin in 2013, both in Chemical Engineering. 
Amanda continues to engage in the broader scientific community.  She has co-authored 18 peer-reviewed 
publications, including 7 since joining BMS, and presented her work at 7 scientific conferences in the past 5 
years.  She also serves as a guest editor for Current Opinion in Biotechnology’s Pharmaceutical Technology 
issue, and was recently invited to serve on the scientific advisory board for a PhD training program in Systems 
Biology. 
Amanda has consistently demonstrated an interest in mentorship and STEM education.  Since 2011, she serves 
as an alumni interviewer for MIT, volunteering her free time to meet with high school students to answer 
questions about MIT and share her experience as an alumna.  She serves on the BMS University Relations team 
where she has championed a new initiative to partner with faculty across the country and build relationships 
with schools outside of the Northeast region.  She also developed and led a program called “BMS Women in 
ChemE Exploration Day”.  This annual event brings female chemical engineering undergraduate students from 
neighboring universities on-site for a day to learn about careers in BioPharma.  The program is intended to 
inspire more female engineering talent to consider long term careers in the Bioprocessing field. 
Previous winners of this award are Colin Clarke (Dublin City University, Ireland), Corinne Hoesli (McGill 
University, Canada), and Huong Le (Amgen). 
Welcome from the CCE XVI Chairs 
 
Welcome everyone to Saddlebrook, the legendary resort in Tampa, FL, for the 16th Cell Culture 
Engineering (CCE) conference!  As we celebrate the 30th anniversary of our meeting it is exciting 
that our meeting continues to be the premiere cell culture engineering conference and continues 
to shape the direction of cell culture technologies and growth of the biotechnology industry. 
Throughout this time, the CCE series has also been the main forum where industry and academia 
meet to assess the science and technology progress in the field and to guide trends and establish 
good practices.  
 
With over 400 participants from 24 countries on 5 continents, this year’s meeting is certainly one 
of the largest ECI conferences ever, and one of the most diverse to date involving many students, 
academics, government, and industry representatives to invest in the future and sustain the 
growth of the cell culture engineering industry. We will have the largest number of academics and 
students ever to attend the meeting and this is made possible by the generous sponsorship from 
our industry partners. To welcome new members of our community and to increase interactions 
with our community early in their career, whether in academia or industry, we are introducing a 
new opening segment to the conference on Sunday afternoon. This opening segment will include 
short presentations followed by a networking session.  The conference program includes more 
than 50 oral presentations, four keynote addresses and two award lectures.  In addition, we have 
eight thematic workshops and ~ 200 posters.  As has been the tradition and a key success factor 
of this conference series, a significant amount of time has been allocated to poster sessions. You 
are invited and strongly encouraged to take full advantage of this opportunity to explore and 
discuss the large body of interesting and excellent work that will be presented in these sessions. 
 
Cell culture technologies continue to fuel the growth of biologics based medicines and 2017 was 
a banner year with more than 15 new products being approved in the US. Last year was 
particularly significant, as our industry also contributed to two new classes of medicines, being 
hailed as “cures”.  The US FDA approved two medicines in the field of adoptive cell therapy and 
another in gene therapy that will no doubt spur significant new innovation in the field of cell culture 
technologies.  In addition, five biosimilars were approved and the technological innovation needed 
to increase global access for our life changing medicines is more urgent than ever. In 2017 we 
also saw cancer patients beginning to realize the true potential of immunotherapies and the 
regulators are challenging the biotechnology industry to speed up the development of these life-
changing medicines.  In addition, medicines with novel modalities and formats are continuing to 
advance through clinical development and it is clear that current mammalian cell technologies 
need to be adapted and new discoveries are needed to enable successful commercialization of 
these medicines.  With this in mind, we’ve put together a program that will showcase new 
directions, challenges, and successes in the cell culture engineering arena, as shared by leading 
academic and industrial experts. We have introduced a new oral session, “Towards other cell 
lines and systems – Opportunities and Challenges Beyond CHO” that will highlight advances that 
could prove transformative for mammalian cell culture.  Additionally, we have introduced a new 
session focused on cell and gene therapies, that will highlight the opportunities for cell culture 
engineers in this emerging field.  We will also continue with the oral session on “Current Concerns 
and Regulatory Strategies”, with which we aim to highlight the most current challenges facing our 
community, be they derived from accelerated programs, the entry of biosimilars, or novel 
therapies.  We have also introduced a workshop session that will challenge cell culture engineers 
to innovate to increase global access of biologics.  Finally, as a celebration of 30th Anniversary of 
Cell Culture Engineering conference, we are honored to have Wei-Shou Hu, the chair of CCE I 
and II, teaming up with Weichang Zhou, the chair of CCE XIV, to host a plenary session titled “30 
years of Cell Culture Engineering”. We strongly encourage each one of you to engage in the 
dialogue that is enabled by this conference venue, sharing your thoughts and expertise with 
others as we collectively shape the future of cell culture engineering.   
 
We also invite you to enjoy the warmth of the Tampa area and the Saddlebrook resort, especially 
those of you that are waiting for winter to end in 2018.  The resort is located on 480 acres of rolling 
terrain surrounded by lagoons and cypress trees.  Saddlebrook was purposely planned as a car-
free “walking village” ensuring guests can easily walk throughout the entire resort.  The resort’s 
540 suites showcase an inviting rich tropical design and are clustered around nine serene 
courtyards complete with gardens, stone benches, stone paver walkways, and native lush Florida 
landscaping.   In listening to the feedback from prior conferences, we have arranged the schedule 
to provide you with free time on Wednesday morning, and we hope you will take advantage of the 
many opportunities at the resort that include two Arnold Palmer signature golf courses and a 
championship tennis complex that features 45 courts including four Grand Slam surfaces.  The 
Sports Village features two adjacent fitness centers, one sand and two grass volleyball courts, a 
regulation-size basketball court, and three swimming pools including the Superpool, a half-million 
gallon free-form pool.  We look forward to having you all at a memorable gala dinner where we 
will recognize the next winner of the Cell Culture Engineering award, recognize some of the 
outstanding posters presented here, learn of the chairs for the next CCE to be held in 2020, and 
enjoy our last opportunity together to network and enjoy the camaraderie of our incredible cell 
culture community.   
 
We would like to thank all the oral session chairs, workshop program and session chairs, and 
poster session chairs, all of whom have worked with remarkable dedication to put together a 
balanced and high-quality program.  And, once again, thanks to the generous contributions from 
our corporate sponsors for enabling our outstanding academic attendance. 
 
We would also like to convey to our cell culture community a message of regret at not having 
been able to accept many colleagues from Academia and Industry who were interested in 
participating in this event. Clearly, this conference continues to be in high demand.  But, the 
implicit working principle of keeping the conference with a size of participants that would maximize 
interactions among scientists and engineers while still allowing efficient cross-fertilization between 
different sectors makes it difficult to accommodate all requests to attend.   
 
Finally, special thanks to Barbara Hickernell and her dedicated team at ECI, particularly Kathy 
Chan, Kevin Korpics, and Tressa D’Ottavio for their tireless help and enormous assistance with 
the logistics and details. Certainly, many of you received personalized emails from Kathy in 
managing the invitation and registration process.  We hope that this conference will live up to the 
high standard that has been set for the CCE series by preceding Chairs.  We also want to thank 
the many student volunteers, and Saddlebrook resort staff, for helping make this meeting a 
success.   
 
Once again, welcome to Saddlebrook and the beautiful Tampa Bay area, and a warm welcome 
to Cell Culture Engineering XVI. We look forward to meeting each of you personally.  
 
Anne Skaja Robinson, Gene Schaefer, and Raghavan Venkat 
Chairs, Cell Culture Engineering XVI 
Conference Sponsors 
The organizers wish to express their gratitude to the following companies who, through 
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Room locations and notes 
 
 
• General Sessions will be held in the Royal Palm East, Center, West 1-3. 
• Poster Sessions will be in the Grand Pavilion. All posters will remain mounted for the 
entire conference. Authors of even-numbered posters are asked to stay with their 
presentations on Sunday and Tuesday evenings, and authors of odd-numbered posters 
are asked to stay with their presentations on Monday and Wednesday evenings. 
 Posters must be taken down no later than 9:00 am on Thursday morning. 
• The locations for workshops are listed in the program. 
• All breakfasts and lunches will be in the Commons and Pegasus Ballroom. 
• Dinner locations are listed in the program. 
• Coffee breaks will be in the Royal Palm Foyer. 
• The ECI office is in Boardroom C. 
• Boardroom D is available for small ad hoc meetings during the week. Please see ECI 
staff if you would like to schedule a meeting. 
• Audio, still photo and video recording by any device (e.g., cameras, cell phones, laptops, 
PDAs, watches) is strictly prohibited during the technical sessions, unless the author and 
ECI have granted prior permission. 
• Speakers – Please have your presentation loaded onto the conference computer prior to 
the session start (preferably the day before). 
• Speakers – Please leave discussion time as previously directed by your session chair. 
• Please do not smoke at any conference functions. 
• Turn your mobile telephones to vibrate or off during technical sessions. 
• Please write your name on your program so that it can be returned to you if lost or 
misplaced. 
• After the conference, ECI will send an updated participant list to all participants. Please 
check your listing now and if it needs updating, you may correct it at any time by logging 
into your ECI account. 
• Emergency Contact Information: Because of privacy concerns, ECI does not collect or 
maintain emergency contact information for conference participants.  If you would like to 
have this information available in case of emergency, please use the reverse side of 





    
 
Sunday, May 6, 2018 
 
12:30 – 17:30 Conference Registration (Royal Palm Foyer) 
 
15:00 – 15:15 Opening Remarks 
Anne Skaja Robinson, Tulane University, USA 
Raghavan Venkat, MedImmune, USA 
Gene Schaefer, Janssen, USA 
 
 
Session 1: Views from the Younger Generation (and the Young at Heart) 
Session Chairs: Neil Templeton, Merck & Co., Inc, USA 
                          Josh Leonard, Northwestern University, USA 
                          Derrick Scott, Delaware State University, USA 
 
15:15 – 15:20 Introduction 
Neil Templeton, Merck & Co., Inc., USA 
Josh Leonard, Northwestern University, USA 
Derrick Scott, Delaware State University, USA 
 
15:20 – 16:50 Short Poster Highlights 
 
16:50 – 17:30 Break and Networking time 
 
17:30 – 18:15 Keynote 
The human protein atlas: Implications for human biology, drug development, and 
precision medicine 
Mathias Uhlén, KTH Royal Institute of Technology and Karolinska Institute, Sweden 
 
18:30 – 20:30 Dinner (Key West Buffet in Commons Area) 
 
20:30 – 22:30 Poster Session and Reception (sponsored by MilliporeSigma) 
(Authors of even-numbered posters are asked to stay with their posters) 
 
Poster Chairs: 
Anthony Grippe, Merck & Co., Inc., USA 
Weiwei Hu, Celgene, USA 
Devesh Radhakrishnan, BioMarin, USA 
Nicholas Sandoval, Tulane University, USA 
  
Monday, May 7, 2018 
 
06:30 – 08:00 
 
Breakfast 
Organizing Committee Breakfast Meeting 
 
08:00 – 08:10 Opening Remarks 
Anne Skaja Robinson, Tulane University, USA 
Raghavan Venkat, MedImmune, USA 
Gene Schaefer, Janssen, USA 
 
 Session 2:  Towards Other Cell Lines and Systems: Opportunities and Challenges 
Beyond CHO (sponsored by Lonza) 
Session Chairs: Véronique Chotteau, KTH Royal Institute of Technology, Sweden 
                          Rashmi Kshirsagar, Biogen, USA 
 
08:20 – 08:45 Moving Beyond CHO: Alternative host systems may be the future of 
biotherapeutics 
Christina Alves, Biogen, USA 
 
08:45 – 09:10 
 
Insect cell platforms for production of pseudo-typed VLPs for drug and vaccine 
development 
Antonio Roldao, iBET - Instituto de Biologia Experimental e Tecnológica, Portugal 
 
09:10 – 09:35 Production of biopharmaceuticals in an intensified perfusion process of HEK 293 
cells 
Johan Rockberg, KTH Royal Institute of Technology, Sweden 
 
09:35 – 10:00 Beyond CHO cells: Cell-free protein synthesis for biotherapeutics 
Bob Kiss, Sutro Biopharma, USA 
 
10:00 – 10:30 Coffee Break  
 
 
Session 3: Impact of Novel Gene Editing Approaches to Engineering and 
Developing Cell Lines (sponsored by Genentech) 
Session Chairs: Kris Chan, Michigan State University, USA 
                          Karin Anderson, Pfizer, USA 
 
10:40 – 11:05 Engineering CHO cells for the production of "Hard-To-Produce" proteins 
Bjørn Voldborg, Technical University of Denmark, Denmark 
 
11:05 – 11:30 CRISPR/Cas9 mediated knockout of microRNAs for precise cell engineering 
Kerstin Otte, University of Applied Sciences Biberach, Germany 
 
11:30 – 11:55 miR-CATCH identifies biologically active miRNA regulators of the pro-survival 
gene XIAP, in Chinese hamster ovary cells 
Paul Kelly, National Institute for Bioprocessing Research and Training(NIBRT), Ireland  
 
11:55 – 12:20 Glycoengineering of CHO cells for production of recombinant therapeutics with 
enhanced efficacy 
Zhiwei Song, A*STAR Bioprocessing Technology Institute, Singapore 
 
 
Monday, May 7, 2018 (continued) 
 
12:20 – 12:45 Elimination of the “Essential” Warburg effect in CHO cells through a multiplex 
genome engineering strategy 
Nate Lewis, University of California, San Diego, USA 
 
12:45 – 14:00 Lunch  
 
14:00 – 15:30 Workshops (Four concurrent) 
 
Increasing Speed to the Clinic and Market B (Lagoon Pavilion) 
(Sponsored by Amgen and Bristol-Myers Squibb) 
Facilitators: Kevin Smith (Janssen R&D), Matt Croughan (Keck Graduate Institute), Inn 
Yuk (Genentech) 
  
Advances and Challenges with Tech Transfer, Scale-up, and Comparability 
(Pegasus South) 
(Sponsored by Celgene, GE Healthcare and Novo Nordisk) 
Facilitators: Anurag Khetan (BMS), Kara Calhoun (Genentech) 
 
Opportunities and challenges of adopting decades of cell culture knowledge for 
cell and gene therapy development (Royal Palm East 1-3) 
(Sponsored by BioMarin, Gilead Sciences and Irvine Scientific) 
Facilitators: Chapman Wright (Biogen), Amine Kamen (McGill University), John Pierciey 
(bluebird bio) 
 
How can interactions within the ‘biomanufacturing ecosystem’ deliver value? 
(Pegasus Ballroom East) 
(Sponsored by Janssen R&D and NIIMBL) 
Facilitators: Tim Charlebois (Pfizer), Mike Betenbaugh (Johns Hopkins University) 
 




Session 4:  Regulatory Strategies and Concerns in Current and Emerging 
Therapies 
Session Chairs: Chris Frye, Eli Lilly, USA 
                          Bill Bentley, University of Maryland, USA 
                          Pranhitha Reddy, Gene-to-BLA, USA 
  
16:05– 16:30 Limitations of subcloning as a tool to characterize homogeneity of a cell 
population 
Jennitte Stevens, Amgen, USA 
 
16:30 – 16:55 Registration enabling campaign for accelerated development: A PPQ strategy 
with minimal early investments to enable fast to market development for a 
promising monoclonal antibody 
Jessica Wuu, Genentech, USA 
 
16:55 – 17:20 Derivation of process control strategy for biosimilar: Is it different from the way a 
control strategy is derived for a novel biologic? 
Dinesh Baskar, Biocon Research Limited, India 
 
17:20 – 17:45 Confronting the Analytical Challenges of Chimeric Antigen Receptor T Cell 
Heidi Zhang, Juno Therapeutics, USA 
Monday, May 7, 2018 (continued) 
 
17:45 – 18:30 
 
Cell Culture Engineering Award Lecture 
Large scale production and characterization of exosomes 
Konstantin Konstantinov, Codiak BioSciences, USA 
 
18:30 – 20:30 Dinner (18th Fairway of the Saddlebrook Golf Course) 
 
20:30 – 22:30 Poster Session and Reception (sponsored by Roche and Solentim) 
(Authors of odd-numbered posters are asked to stay with their posters) 
 
  
Tuesday, May 8, 2018  
 
06:30 – 08:00 Breakfast 
Organizing Committee Breakfast Meeting   
 
08:00 – 08:05 Opening Remarks 
Anne Skaja Robinson, Tulane University, USA 
Raghavan Venkat, MedImmune, USA 
Gene Schaefer, Janssen, USA 
 
08:05 – 08:50 Keynote  
Cell Culture Bioprocess Learnings: Past successes and future challenges 
Günter Jagschies, GE Healthcare Life Sciences, Germany 
 
 
Session 5: Pushing the Limits on Process Intensification: 10 g/L and Beyond  
Session Chairs: Greg Hiller, Pfizer, USA 
                          Marcella Yu, Boehringer Ingelheim, USA 
 
09:00 – 09:30 Intensification of a multi-product perfusion platform – managing growth 
characteristics at high cell density for maximized volumetric productivity  
Shawn Barrett, Sanofi, USA 
 
09:30 – 10:00 Evolution of TFF-based perfusion: A path towards non product sieving and direct 
chromatography integration 
Nuno D. S. Pinto, Merck & Co., Inc., USA 
 
10:00 – 10:30 Coffee Break  
 
10:30 – 11:00 Development towards a high-titer fed-batch CHO platform process yielding 
product titers > 10 g/L 
Laurel Zhang, Genentech, USA 
 
11:00 – 11:30 Development of a novel automated perfusion mini-bioreactor ambr® 250 perfusion
Barney Zoro, Sartorius, UK 
 
11:30 – 12:00 
 
 
Intensified cell culture using a linked bioreactor system  
Matthew Gagnon, Pfizer, USA 
 
















Tuesday, May 8, 2018 (continued) 
 
13:30 – 15:00 
 
Workshops (Four concurrent) 
 
Increasing Global Access to Biotherapeutics: What Role Does Upstream Play? 
(Lagoon Pavilion) 
(Sponsored by Boehringer Ingelheim, MedImmune and Shire) 
Facilitators: Brian Kelley (Vir), Jeff McGrew (Just Biotherapeutics) 
  
Advances in Cell Line Engineering and Protein Expression Strategies (Pegasus 
South) 
(Sponsored by Eli Lilly and Company and Merck and Co., Inc.) 
Facilitators: Steven Lang (Genentech), Diane Hatton (MedImmune) 
 
Applications of ‘Omics Tools in Cell Culture (Royal Palm East 1-3) 
(Sponsored by AbbVie and Biogen) 
Facilitators: Mike Laird (Genentech), Nate Lewis (University of California, San Diego), 
Bhanu Mulukutla (Pfizer) 
 
PAT Implementation: Key Challenges and Opportunities (Pegasus Ballroom East) 
(Sponsored by Eppendorf AG, GlaxoSmithKline and Sartorius Stedim Biotech) 
Facilitators: Kelly Wiltberger (Biogen), Stephen Goldrick (University College London) 
 
15:00 – 15:30 Coffee Break 
 
15:30 – 16:15 
 
Keynote  
CAR T Cell Therapy: Fifteen years of academic driving 
Isabelle Rivière, Memorial Sloan Kettering Cancer Center, USA 
 
 Session 6 - Innovation in Cell and Gene Therapies 
Session Chairs: Greg Russotti, Celgene Corporation, USA 
                          Eleftherios T Papoutsakis, University of Delaware, USA 
 
16:25 – 16:50 
 
Engineered CAR T cell therapy for solid tumors 
Juan F Vera, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas 
Children’s Hospital, USA 
 
16:50 – 17:15 
 
iPSC-derived neurospheroids recapitulate development and pathological 
signatures of human brain microenvironment  
Catarina Brito, iBET - Instituto de Biologia Experimental e Tecnológica, Portugal 
 
17:15 – 17:40 
 
Biomanufacturing of platelet-like cells and cell microparticles for cell therapy 
applications 
Eleftherios T Papoutsakis, University of Delaware, USA 
 
17:40 – 18:05 
 
CAR T manufacturing: process modifications for a transformational autologous 
product on a rapid path to licensure 
Thomas Brieva, Celgene, USA 
 
18:05 – 18:30 
 
Development of a large scale GMP compliant suspension cell culture system for 
the manufacturing of allogenic Exosome-based biotherapeutics  
Scott Estes, Codiak BioSciences, USA 
 
18:30 – 20:30 Dinner on your own 
Tuesday, May 8, 2018 (continued) 
 
20:30 – 22:30 
 
Poster Session and Reception (sponsored by Wuxi Biologics) 
(Authors of even-numbered posters are asked to stay with their posters) 
 
  
Wednesday, May 9, 2018 
06:30 – 08:00 Breakfast 
 
11:00 – 12:00 Grab ‘n Go lunches (in Foyer) 
 
08:00 – 12:30 Networking Time  
 
Session 7 - Process Scale Up/Down, Characterization and Control Strategy 
Definition (sponsored by Kerry) 
Session Chairs: Shailen Singh, Merck and Co., Inc., USA 
                          Gary Lye, University College London, UK 
 
12:35 – 13:00 Probing lactate metabolism variations in large-scale bioreactors 
Sen Xu, Merck and Co., Inc., USA 
 
13:00 – 13:25 
 
 
Medium development strategies and scale down models for a high density high 
productivity cell line 
Amy Johnson, Regeneron, USA 
 
13:25 – 13:50 Process scale up and characterization of an intensified perfusion process 
Jiuyi Lu, Sanofi, USA 
 
13:50 – 14:15 Leveraging a technical partnership to deliver high titer biologics manufacturing 
Haofan (Eric) Peng, Biogen, USA 
 
14:15 – 14:40 Efficient technology transfers to increase agility, flexibility, and productivity 
Kara Calhoun, Genentech, USA 
 
14:40 – 15:05 Towards advanced understanding of scale-up: From computational fluid 
dynamics to systems biotechnology approaches 
Jochen Schaub, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany 
 
15:05 – 15:45 Martin Sinacore Award Lecture 
Understanding and improving cell culture processes through omics technologies
Amanda Lewis, Bristol-Myers Squibb, USA 
 
15:45 – 16:15 Coffee Break 
 
 Session 8: Computational Strategies to Enhance Bioprocess Performance 
Session Chairs: Amanda Lewis, Bristol-Myers Squibb, USA 
                          Colin Clarke, National Institute for Bioprocessing Research and  
                          Training (NIBRT), Ireland 
 
16:25 – 16:50 Application of -omics knowledge yields enhanced bioprocess performance 
Rashmi Kshirsagar, Biogen, USA 
 
16:50 – 17:15 Multivariate data analysis enabling improved clone selection 
Stephen Goldrick, University College London/MedImmune, UK 
 
17:15 – 17:40 Quantifying the partition of metabolic resources between cellular and 
recombinant protein glycosylation in GS-CHO cells 
Ioscani Jimenez del Val, University College Dublin, Ireland 
Wednesday, May 9, 2018 (continued) 
 
17:40 – 18:05 More accurate process understanding from process characterization studies 
using Monte Carlo simulation, regularized regression, and classification models 
Cary Opel, Gilead Sciences, USA 
 
18:05 – 18:30 Enhancing CHO process understanding from CHO manufacturing process data 
Tom Mistretta, Amgen, USA 
 
18:30 – 18:55 Gaussian mixture models and machine learning predict megakaryocytic growth 
and differentiation potential ex vivo 
William M. Miller, Northwestern University, USA 
 
19:00 – 20:30 Dinner (Poolside A) 
 
20:30 – 22:30 Poster Session and Reception 
(Authors of odd-numbered posters are asked to stay with their posters) 
 
  
Thursday, May 10, 2018 
 
06:30 – 08:00 Breakfast 
Steering Committee Breakfast Meeting   
 
08:00 – 08:05 Opening Remarks 
Anne Skaja Robinson, Tulane University, USA 
Raghavan Venkat, MedImmune, USA 
Gene Schaefer, Janssen, USA 
 
 
Session 9: Advanced Cell Culture Processes with an Emphasis on New Analytical 
and Computational Technology 
Session Chairs: Arthi Narayanan, Genentech, USA 
                          Cleo Kontoravdi, Imperial College London, UK 
 
08:20 – 08:45 
 
 
Automated and enhanced clone screening using a fully automated microtiter 
plate-based system for suspension cell culture 
Sven Markert, Roche Diagnostics GmbH, Germany 
 
08:45 – 09:10 
 
Systems biology approach in the development of chemically-defined media for 
production of protein therapeutics in Chinese hamster ovary cells  
Wai Lam Ling, Merck and Co., Inc., USA 
 
09:10 – 09:35 Feedback control of lactate using Raman spectroscopy 
Peter Slade, Pfizer, USA 
 
09:35 – 10:05 Coffee Break  
 
10:05 – 10:30 An energy-based modelling tool for culture medium design and  
biomanufacturing optimization  
Athanasios Mantalaris, Imperial College London, UK 
 
10:30 – 10:55 Novel modeling methodology to predict product quality and cell culture 
performance in fed-batch and perfusion cultures 
Bassem Ben Yahia, UCB Pharma S.A., Belgium 
 
10:55 – 11:45 Keynote 
From bioreactors for protein therapeutic production to bioreactors for testing 
efficacy and safety of protein therapeutics 
Linda Griffith, Massachusetts Institute of Technology, USA 
 
11:45 – 13:15 Lunch  
 
 Session 10: Advances In Cell Culture Control of Product Quality Attributes 
(sponsored by Regeneron Pharmaceuticals, Inc.) 
Session Chairs: Martin Gawlitzek, Genentech, USA 
                          Seongkyu Yoon, University of Massachusetts, Lowell, USA  
 
13:20 – 13:45 Tailoring antibody glycosylation via integrating genome and protein engineering 
to generate preferred glycoforms on the Fc region 
Mike Betenbaugh, Johns Hopkins University, USA 
 
Thursday, May 10, 2018 (continued) 
 
13:45 – 14:05 Product quality control strategy development for non-mAb complex modalities by 
using combinatorial cell engineering and OMICS screening tools 
Zhimei Du, Merck and Co., Inc., USA 
 
14:05 – 14:25 Controlling tryptophan oxidation through medium/feed modifications and 
potential MOA unveiled by transcriptomics analysis 
Luhong He, Eli Lilly, USA 
 
14:25 – 14:45 
 
Online control of cell culture redox potential prevents antibody reduction 
Michael Handlogten, MedImmune, USA 
 
14:45 – 15:05 Identification of copper as a cell culture media component causing metabolite 
depletion and product sequence variants 
Brian Mickus, Gilead Sciences, USA 
 
15:05 – 15:30 
 
A synthetic biology based cell line engineering pipeline 
Wei-Shou Hu, University of Minnesota, USA 
 
15:30 – 16:00 Break  
 
 Session 11: 30 Years of Cell Culture Engineering  
Session Chairs: Weichang Zhou, WuXi Biologics, China 
                          Wei-Shou Hu, University of Minnesota, USA 
 
16:15 – 16:40 Engineering stem cell fate 
Peter Zandstra, University of British Columbia, Canada 
 
16:40 – 17:05 Future challenges in biologics cell culture engineering 
Mike Laird, Genentech, Inc., USA 
 
17:05 – 17:30 Ignorant empiricism in cell culture engineering:  30 years of expensive lessons 
Matt Croughan, Keck Graduate Institute, USA 
 
17:30 – 18:30 Panel Discussion 
 
18:30 – 19:30 Reception 
 
19:30 – 21:00 Banquet (Pegasus Ballroom)  












Friday, May 11, 2018 
 
06:30 – 10:00 Networking Breakfast and Departure 
 







Clonality and Stability 
 
1 Limitations of subcloning as a tool to characterize homogeneity of a cell population 
Hedieh Barkhordarian, Amgen Inc., USA 
 
2 Interrogating cell culture populations for the selection of production cell lines using 
microfluidic culturing, single cell analysis, and predictive modelling 
Kim Le, Amgen Inc., USA 
 
3 Rethinking clonality using modeling approaches 
Chun Chen, Amgen Inc., USA 
 
4 Tools and methods for providing assurance of clonality for legacy cell lines 
Paul Wu, Bayer HealthCare, USA 
 
5 Variation in karyotype and chromsome numbers in CHO cell lines and subclones 
Nicole Borth, BOKU University, Austrian Center of Industrial Biotechnology, Austria 
 
6 Genomic understanding of clonal variation in recombinant CHO cells 
Gyun Min Lee, KAIST, South Korea 
 
7 Characterisation of Chinese Hamster Ovary (CHO) cells at the single cell level 
Eva Pekle, MedImmune, United Kingdom 
 
8 Population dynamics in cloned CHO cell lines 
Tzihsuan Jennifer Lin, Pfizer Inc., USA 
 
9 The relationship between clonality, cellular heterogeneity, and process consistency 
Jack J. Scarcelli, Pfizer Inc., USA 
 
10 Process improvement delivered by a high efficiency, automated single cell cloning 
system 
Andrea Gough, Solentim Ltd., United Kingdom 
 
11 Using nanoscale bioreactors to characterize sub-populations of CHO clones and 
screen transfected pools 
Tanner Nevill, Berkeley Lights, Inc., USA 
 
12 Quantification of genomic DNA repair capabilities in CHO and identification of genes 
impacting genomic stability 
Philipp N. Spahn, University of California, San Diego, USA 
 
13 Analysis of DNA DSB repair and production stability in CHO cells 
Xiaolin Zhang, University of Delaware, USA 
 
14 Integrated analysis of genomic and epigenomic instability for CHO cell line 
engineering 
Sofie O'Brien, University of Minnesota, USA 
 
  
I: Towards Other Cell Lines and Systems 
 
15 The C1 gene expression system, disrupting the way biologic vaccines, and drugs are 
developed & manufactured 
Ronen Tchelet, Dyadic International Inc, USA 
 
16 Opportunities to leverage cell culture technology to create sustainable food systems: 
The development of "Clean Meat" 
Liz Specht, Good Food Institute, USA 
 
17 Expanding the vector toolkit for complex recombinant protein expression 
Peter M. O'Callaghan, Lonza Biologics, USA 
 
18 Identifying Hipk1 as a target of Mir-22-3p enhancing recombinant protein production 
from Hek 293 by using microarray and Htp sirna screen 
Sarah Inwood, National Institutes of Health (NIH), USA 
 
19 spERt Technology: A novel strategy to improve productivity through enhanced 
polyribosome assembly on the endoplasmic reticulum in CHO cells 
Kiyoko Ogawa-Goto, Nippi Research Institute of Biomatrix, Japan 
 
20 Newly established cell lines derived from Chinese hamster for production of biologics 
Takeshi Omasa, Osaka University, Japan 
 
21 Improving vaccine production with a serum-free medium for MRC-5 cells 
Anna-Barbara Hachmann, Thermo Fisher Scientific, USA 
 
22 Use of a ‘molecular tug’ to overcome limitations in the production of ‘difficult to 
express’ recombinant proteins 
Hirra Hussain, University of Manchester, United Kingdom 
 
II: Computational Strategies to Enhance Bioprocess Performance 
 
23 Improving bioreactor design through pH mapping of bioreactors employing 
Computational Fluid Dynamics coupled with equilibrium calculations 
Natraj Ram, AbbVie, USA 
 
24 Empowering manufacturing decisions through process simulation models 
Tiffany Rau, BioProcess Technology Consultants, USA 
 
25 Applying genome scale metabolic models integrated with OMICs technologies for 
improvemwent of commercial CHO cell culture process 




27 A bioinformatics approach to genome to phenome predictions in CHO cell lines 
Derrick Scott, Delaware State University, USA 
 
28 Multiscale modeling of monoclonal antibody (mAb) production and glycosylation in a 
CHO cell culture process 
Yu Luo, University of Delaware, USA 
 
29 Bioprocess intelligent for the improvements and prediction on fed-batch cell culture in 
bioreactor 
Ching-Jen Yang, Development Center for Biotechnology, Taiwan 
30 Development of an in silico molecule assessment method for product expression 
Misha Lazebnik, Genentech, Inc., USA 
 
31 Monitoring the production of AAV vectors in insect cells by fluorescence 
spectroscopy 
Daniel Alexandre Marques Pais, Instituto de Biologia Experimental e Tecnológica (iBET), 
Portugal 
 
32 Towards model-based bioprocess characterization: A mathematical model of cell 
cycle, metabolism and apoptosis of mAb-producing mammalian cells 
António Lima Grilo, Imperial College London, United Kingdom 
 
33 Application of a genome-based predictive CHO model for increased mAb production 
and Glycosylation control 




35 Dynamics of intracellular metabolite pools in MDCK suspension cells during growth 
and influenza virus infection 
Thomas Bissinger, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
36 Application of metabolomics and fluxomics to increase productivity and predict 
product quality 
Neil Templeton, Merck & Co., Inc., USA 
 
37 Characterizing the effect of glutamine supplementation on asparagine and glutamine 
metabolism using 13C metabolic flux analysis 
Sandra V. Bennun, Regeneron Pharmaceuticals Inc., USA 
 
38 Innovative metabolic data integration applicable for Therapeutic Protein Development 
2.0 
Wolfgang Paul, Roche Diagnostics GmbH, Germany 
 
39 Biologically consistent annotation of CHO cell culture metabolomics data 
Nicholas Alden, Tufts University, USA 
 
40 Curation of a CHO DG44 genome scale model and application to support cell culture 
development process 
Cyrielle Calmels, UCB Pharma and Technical University of Denmark, Belgium 
 
41 Filling the gap between experimentalists and modelers by determining a mammalian 
cell's metabolic capabilities based on transcriptomic data 
Anne Richelle, University of California, San Diego, USA 
 
42 A priori optimization of cell culture feeds using metabolic engineering 
Nicholas Trunfio, University of Massachusetts Lowell and US Food and Drug Administration, 
USA 
 
43 Media formulation optimization based on multi-scale modeling of heterogeniety in 
mammalian cell culture process 
Shaun Galbraith, University of Massachusetts Lowell, USA 
 
44 RNA-seq data reveals metabolic regulation in Chinese Hamster Ovary cell culture 
Sha Sha, University of Massachusetts Lowell, USA 
45 Metabolic pathway engineering in mammalian cells through kinetic model optimization 
Conor M. O'Brien, University of Minnesota, USA 
 
46 Epigenetic regulation of gene expression in response to a changing environment in 
CHO cell batch culture 
Heena Dhiman, University of Natural Resources and Life Sciences, Vienna, Austrian Center 
of Indistrial Biotechnology, Austria 
 
47 13C flux analysis in industrial CHO cell culture applications 
Jamey Young, Vanderbilt University, USA 
 
III: Advances in Cell Culture Control 
 
48 Controlling continuous high cell density perfusion culture with the Alternating 
Tangential Flow system in real time using radio-frequency impendance 
Aditya Bhat, Aber Instruments Ltd, USA 
 
49 Demonstrating a powerful scale-up strategy for Biosimilar mAb in single use systems 
via physicochemical and functional characterization 
Serdar Alpan, Turgut Ilaclari A.S., Turkey 
 
50 Impact of raw materials on sialyation for a therapeutic protein 
Wei-Chien Hung, Alexion, USA 
 
51 Delivery of consistent and high-quality antibody therapeutics by actively monitoring 
and controlling critical quality attributes 




53 Modulation of half antibody and aggregate formation in a CHO cell line expressing a 
bispecific antibody 
Natalia Gomez, Amgen, USA 
 
54 Controllability analysis to identify manipulated variables for a glycosylation control 
strategy 
Melissa M. St. Amand, Belcan Corporation, DARPA, USA 
 
55 A novel additive for controlling glycosylation of monoclonal antibodies 
Fernie Mitchelson, Biogen, USA 
 
56 Perfusion cell culture: Challenges and potentials between lab and manufacturing scale 
Daniel J. Karst, Biogen, Switzerland 
 
57 Process optimization for high volumetric productivity with product quality control 
Rashmi Kshirsagar, Biogen, USA 
 
58 Study of an unusually high level of N-glycolylneuraminic acid (NGNA) sialylation on a 
monoclonal antibody expressed in Chinese hamster ovary cells 
Shumin Yang, Boehringer Ingelheim Fremont Inc, USA 
 
59 A Master Cell Bank (MCB) banking troubleshooting case study: Challenges and 
process improvements with comprehensive root cause analysis 
Lianchun Fan, Bristol-Myers Squibb Company, USA 
 
60 Effect of lactate media concentration on induced pluripotent stem cell proliferation 
and metabolism 
Daniel Odenwelder, Clemson University, USA 
 
61 Strategies to modulate charge variants of a Biosmilar monoclonal antibody through 
cell culture conditions 




63 Generating glycan variants for biological activity testing by means of parallel 
experimental design and multivariate analysis 
David Bruehlmann, EMD Serono, Switzerland 
 
64 A systematic approach for process development and quality control in continuous 
perfusion cultures 
Moritz Wolf, ETH Zurich, Switzerland 
 
65 Genotype of CHO host cell line has higher impact on mAb production and quality than 
process strategy or cell culture medium 
Andreas Castan, GE Healthcare, Sweden 
 
66 Maintaining product quality from early to late stage process development 
Jason C. Goodrick, Genentech, Inc., USA 
 
67 Effects of cryopreservation on recombinant CHO cell lines 
Inn Yuk, Genentech, Inc., USA 
 
68 Improving glycosylation profiles and cell culture performance with a sensitive cell line 
in commercial manufacturing 
Lisa L. Vulliet, Genentech, Inc., USA 
 
69 Evaluation of Raman spectroscopy for online monitoring of cell culture product quality 
Barbara Chiang, Genentech, Inc., USA 
 
70 Using PLS to understand potential sources of process variation & assessing medium 
components to alter afucosylation 
Angela Meier, Genentech, Inc., USA 
 
71 Comprehensive manipulation of glycosylation profiles across development scales 
Sven Loebrich, ImmunoGen, USA 
 
72 Controlling fab terminal sialylation of antibodies through culture conditions 
Calum McIntosh, Imperial College London, United Kingdom 
 
73 Elucidating amino acid metabolism in CHO cells 
Michael J. Betenbaugh, Johns Hopkins University, USA 
 
74 Towards a universal CHO reference platform with epigenome characterization for the 
biotechnology community 
Michael Betenbaugh, Johns Hopkins University, USA 
 
75 Intact glycopeptide analysis of recombinant protein from CHO cells 
Qiong Wang, Johns Hopkins University, USA 
 
76 Modulation of Mannose levels in N-linked glycosylation through cell culture process 
conditions in order to increase ADCC activity for an antibody Biosimilar 
Shahid Rameez, KBI Biopharma Inc., USA 
 
77 A highly automated, continuous method for developing active controllers of product 
quality attributes in early phase clinical development 
Brandon Downey, Lonza, USA 
 
78 Developing integrated platforms for the generation of cell lines expressing bispecific 
proteins with desired qualities 
Jie Zhu, MedImmune/AstraZeneca, USA 
 
79 Impact of S-sulfocysteine on fragments and trisulfide bond linkages in monoclonal 
antibodies 
Aline Zimmer, Merck KGaA, Germany 
 
80 Process and raw material control strategies to manage variability in charge variant 
species of a monoclonal antibody 
Vijay Janakiraman, Merck & Co., Inc., USA 
 
81 Development of a platform expression system using targeted integration in Chinese 
Hamster Ovary cells 
Scott Bahr, MilliporeSigma, USA 
 
82 Defining scalable cell culture processes for Biosimilar candidates 
Carmen Ho, Momenta Pharmaceuticals, USA 
 
83 Dielectric monitoring of mammalian cells in a bioreactor 
Michael Butler, National Institute for Bioprocessing Research and Training (NIBRT), Ireland 
 
84 HIV-1 envelope vaccine production with improved yields and glycosylation profile 
through mannose supplementation  
J. Isaac Godfroy, National Institute of Allergy and Infectious Disease, USA 
 
85 Control strategies for the regulation of protease clipping during mAb production in 
CHO cells 
Daniel Blackstock, National Institutes of Health (NIH), USA 
 
86 Regulation of recombinant protein expression during CHO pool selection enhances 
high producer frequency 
Yves Durocher, National Research Council Canada, Canada 
 
87 Novel engineered CHO DG44 host cell line demonstrates lowered UPR, increased titers 
and superior quality of recombinant vaccines 
Hussain Dahodwala, National Institutes of Health (NIH), USA 
 
88 Monitor and control of multiple bioreactor parameters using in situ raman 
spectroscopy 
Michelle LaFond, Regeneron Pharmaceuticals Inc., USA 
 
89 Proteolysis of non-IgG molecules in transient HEK293 and stable CHO-K1 
bioprocesses 
Alfred M. Engel, Roche Diagnostics GmbH, Germany 
 
90 Implementing automated pCO2 control in small scale cell culture models 
Lia Tescione, Sanofi, USA 
91 Bioreactor scale down model case study: Ensuring nutrient feed strategy is 
representative of clinical and commercial scale 
Matthew Leith, Seattle Genetics, USA 
 
92 Controlling the product quality attributes of a complex recombinant protein in a high 
cell density perfusion bioreactor process 
Rahul Chelikani, Shire Pharmaceuticals, USA 
 
93 Controlling monoclonal antibody product quality using High Throughput Systems 
(HTS) 
Amlan Das, Teva Pharmaceuticals, USA 
 
94 Comparison of transfection methods on yield of recombinant human IgG1 Fc 
Evan Wells, Tulane University, USA 
 
95 Raman spectroscopic analysis of cell differentiation and death modes 
James M. Piret, University of British Columbia, Canada 
 
96 Proteasome-based selection systems for generation of recombinant CHOK1SV GS-
KO™ cell lines with enhanced productivity 
Daniel Wan, University of Kent and Lonza Biologics PLC, United Kingdom 
 
97 Understanding the zinc induced lactate shift in CHO cell culture at transcriptomics 
level to improve the protein production 
Hemlata Bhatia, University of Massachusetts Lowell, USA 
 
98 Systems engineering N-glycans of recombinant therapeutic proteins 
Meghan G. McCann, University of Minnesota, Twin Cities, USA 
 
99 Antibody charge heterogeneity formation in a mammalian cell culture fed-batch 
process 
Bernhard Sissolak, University of Natural Resources and Life Sciences, Vienna, Austrian 
Center of Indistrial Biotechnology, Austria 
 
IV: Advanced Cell Culture Processes 
 
100 Evaluation of redox potential of the Golgi of CHO cells 
Laura Palomares, Universidad Nacional Autónoma de México, Mexico 
 
101 Use of biocapacitance probes for optimized process control at large-scale 
manufacturing 
Christoffer Bro, Biogen, Denmark 
 
102 Online capacitance probes precisely control cell biomass growth through temperature 
regulation 
Jeffrey Swanberg, Bristol-Myers Squibb Company, USA 
 
103 Evaluation of bioanalyzers for upstream commercial manufacturing 
Pani Apostolidis, Bristol-Myers Squibb Company, USA 
 
104 Boundary of oxidative and overflow metabolism (boom) controller for CHO cell feed 
control 
Kathryn Elliott, Clemson University, USA 
 
105 High-density Vero cell perfusion culture in BioBLU 5p Single-Use Vessels 
Sebastian Selzer, Eppendor AG Bioprocess Center, Germany 
106 High-throughput screening for best clone manufacturing using scale-down models 
Maria Wendt, Genedata AG, Switzerland 
 
107 Substrate kinetics screening method for mitigating low titer yields at large scale 
production 
Beril Ereren, Genentech, Inc., USA 
 
108 Increasing efficiency in cell line development through automated workflows 
David Shaw, Genentech, Inc., USA 
 
109 Improving transient gene expression in CHO-EBNA1 cells 
Eric Grazzini, National Research Council Canada, Canada 
 
110 Novel downstream process and analytical tools developed for Influenza VLP vaccine 
Patricia Alves, Instituto de Biologia Experimental e Tecnológica (iBET), Portugal 
 
111 Use of the Cyto-Mine for rapid generation of high-producing clonal cell lines 
Kevin D. Smith, Janssen Pharmaceutical, USA 
 
112 Investigating the use of integrated analytics and automation to enhance process 
development capabilities 
Melisa Carpio, Sartorius Stedim Biotech (2), USA 
 
113 Transcriptomic signatures classifying CHO quasispecies 
Ankita Singh, Technical University of Denmark, Denmark 
 
114 Development of a CHO production medium utilizing proteomic and metabolomics 
analysis 
Paul Gulde, Thermo Fisher Scientific, USA 
 
115 Rapid process monitoring & control in mammalian cell culture using off-gas mass 
spectrometry analysis 
Hai-Yuan Goh, University College London, United Kingdom 
 




117 Strategies to improve productivity of CHO-S cells expressing an anti-TNFα monoclonal 
antibody with biosimilar potential 
Ana M. Moro, Instituto Butantan, Brazil 
 
VI: Pushing the Limits on Process Intensification 
 
118 Getting more for less: Leveraging epigenetics to increase process yield 
Chris Kwiatkowski, Biogen, USA 
 
119 Product sieving challenges in TFF perfusion cell culture 
Marcella Yu, Boehringer Ingelheim, USA 
 
120 Dipeptides in cell culture - Tools for performance increase and risk reduction 
Christian Kessler, Evonik Nutrition & Care GmbH, Germany 
 
121 Mammalian cell perfusion cultures: “Intensification by growth inhibition” 
Moritz Wolf, ETH Zurich, Switzerland 
 
122 Evaluation of IRES-mediated expression and different signal peptides for the 
development of CHO clones producing an anti-PCSK9 monoclonal antibody 
Thayana Araujo da Cruz, PEQ/COPPE/UFRJ, IQ/UFRJ, Brazil 
 
123 Development of perfusion processes for mAb production aiming at high cell densities 
sustained by low cell-specific perfusion rates 
Renata Alvim, Leda Castilho, Federal University of Rio de Janeiro (UFRJ), Brazil 
 
124 Platform based screening strategies that deliver reliable and high quality continous 
biomanufacturing processes 
Leon Pybus, FUJIFILM Diosynth Biotechnologies, United Kingdom 
 
125 Process intensification: Case study with a CHO-based monoclonal antibody 
production process 
Isam A. Hararah, Genentech, Inc., USA 
 
126 Rapid and flexible scale-down media development and optimization for perfusion 
culture 
James Kevin Y. Tan, Irvine Scientific, USA 
 
127 Development of a chemically defined medium for optimal growth and recombinant 
protein production in HEK293 cells 
Chaya Kataru, Kerry, USA 
 
128 Implications of feeds and supplements on the productivity and quality of recombinant 
proteins produced in CHO cells 
John F. Menton, Kerry, USA 
 
129 Moved to Oral Session 5 
 
130 Cellular behavior in high density perfusion processess 
Delia Lyons, MilliporeSigma, USA 
 
131 Hybrid fed-batch cultures using XCell ATF for better yield and robust clarification 
process 
Shashi Kudugunti, Repligen, USA 
 
132 Evaluation of an n-1 perfusion/high-seed fed-batch technology for the intensification 
of recombinant protein production processes: From AMBR250 to 200 L STR 
Daniel Vazquez Ramirez, Sanofi, Germany 
 
133 Optimization and evaluation of perfusion media in high cell density mammalian cell 
culture systems 
Christopher Brau, Thermo Fisher Scientific, USA 
 
VII: Innovation in Cell and Gene Therapies 
 
134 Producer cell line engineering for large volume manufacturing of therapeutic Aav 
Chapman Wright, Biogen, USA 
 
135 Enhanced cell growth with physiologically relevant media supplements 
Stephen Orzell, Nucleus Biologics, USA 
 
136 Generation of helper virus-free adeno-associated viral vector packaging/producer cell 
lines based on a human suspension cell line 
Kerstin Hein, CEVEC Pharmaceuticals, Germany 
137 Bioprocess optimization for the expansion of early memory T cells in serum-free 
conditions 
Ernesto Scibona, ETH Zurich, Switzerland 
 
138 Heterotypic cell-cell interaction of human stem cells for neural differentiation of hybrid 
spheroids 
Liqing Song, Florida State University, USA 
 
139 Metabolic regulation of functional decline during in vitro expansion of human 
mesenchymal stem cells 
Xuegang Yuan, Florida State University, USA 
 
140 Engineering culture environment of human pluripotent stem cells to direct their 
commitment and maturation towards functional cardiomyocytes: An “-Omics” driven 
approach 
Margarida Serra, Instituto de Biologia Experimental e Tecnológica (iBET), Portugal 
 
141 Scalable lentiviral vector production using stable producer cell lines in perfusion 
mode 
Sven Ansorge, National Research Council, Canada 
 
142 Quantitative characterization of all single amino acid variants of a viral capsid-based 
delivery vehicle 
Danielle Tullman-Ercek, Northwestern University, USA 
 
143 Evaluating a gas-permeable culture surface for the generation of megakaryocytes for 
in-vitro platelet production 
Andres Martinez, Northwestern University, USA 
 
144 Optimization of human T cell expansion ex vivo using serum-free medium and the gas-
permeable rapid expansion cell culture devices (G-Rex) 
Evan R. Zynda, Thermo Fisher Scientific, USA 
 
145 Engineering of exosomes for targeted delivery of therapeutic microRNAs 
Nadja Raab, Biberach University of Applied Sciences, Germany 
 
146 Megakaryocytic microparticles-mediated nucleic acid delivery for gene therapy 
Chen-Yuan Kao, University of Delaware, USA 
 
VIII: Impact of Novel Gene Editing Approaches 
 
147 CRISPR-Cas9 mediated cell line engineering of apoptosis pathways increases 
antibody expression with site-specific modifications for antibody drug conjugation 
Yingchun Lu, Ambrx, USA 
 
148 Challenges in cell culture platform development of mAb production with site-specific 
incorporation of non-natural amino acid for ADC generation 
Weimin Lin, Ambrx, USA 
 
149 Novel transposase tools for cell-line engineering 
Ferenc Boldog, ATUM (formerly DNA2.0), USA 
 
150 Dxb11/taut host cell engineering strategy enabling the establishment of strains 
producing the highest yield of advanced recycling antibodies 
Hisahiro Tabuchi, Chugai Pharmaceutical Co., Ltd., Japan 
 
151 Development of high-producing CHO cell lines through target-designed strategy 
Dalton Chen, Development Center for Biotechnology, Taiwan 
 
152 High-yield antibody production using targeted integration and engineering CHO host 




154 Evolution of rCHO cells under mild ER stress to make them super producers 
Sarika Mehra, IIT Bombay, India 
 
155 Overexpression of the mitochondrial pyruvate carrier increases CHO cell and 
recombinant protein productivity and reduces lactate production 
Dubhe Bulté, Universidad Nacional Autónoma de México, Mexico 
 
156 Rolling cycle translation of circularized infinite open reading frames; fooling the 
ribosome 
Alan Costello, Dublin City University, Ireland 
 
157 CRISPR/Cas9 mediated targeting of microRNA-24 improves the bioprocess phenotype 
of Chinese Hamster Ovary cells 
Niamh Keogh, The National Institute for Bioprocessing Research and Training (NIBRT), 
Ireland 
 
158 Elimination of the Warburg effect in Chinese hamster ovary (CHO) cells improves cell 
phenotype as a protein production platform 
Hooman Hefzi, Novo Nordisk Foundation Center for Biosustainability and University of 
California, San Diego, USA 
 
159 Metabolic engineering of CHO cells towards reduced novel growth inhibitor 
production and amino acid prototropy 




161 Targeted epigenetic glyco-engineering in CHO cells 
Nicolas Marx, University of Natural Resources and Life Sciences, Vienna, Austrian Center of 
Indistrial Biotechnology, Austria 
 
162 Enhancement by reduction - Pushing the N-glycosylation capacity of CHO cells by 
cleaning up the Golgi 
Nina Bydlinski, University of Natural Resources and Life Sciences, Vienna, Austrian Center 
of Indistrial Biotechnology, Austria 
 
IX: Process Scale Up/Down, Characterization and Control Strategy Definition 
 
163 Improving developmental timelines through the generation of predictive scale down 
models 
Nicholas Abu-Absi, AbbVie, USA 
 
164 Upstream process development and scale-up of complex glycoprotein production 
using a long duration perfusion process 
Adriane Schilling and Kumar Dhanasekharan, Amicus Therapeutics, USA 
 
 
165 A systematic approach to implement HTST for legacy mammalian cell culture 
processes 
LiYing Yang, AstraZeneca, USA 
 
166 On-line monitoring and controlling of cell apoptosis in mammalian cell culture 
processes using dielectric spectroscopy 
An Zhang, Biogen, USA 
 
167 Leveraging a deeper understanding of Poloxamer188 to improve cell culture 
processes 




169 Enhancing and enabling advanced process controls - reducing variability at the 
source 
Mats Akesson, Biogen, Denmark 
 
170 Overcoming scale-up challenges for a First-In-Human (FIH) antibody production 
process at the 2000L scale: Successful optimization of bioreactor equipment and 
harvest conditions to improve process performance and product yield 
Meena George, Boehringer Ingelheim Fremont Inc, USA 
 
171 Making large scale processes transparent – The application of CFD and classical 
engineering approaches to mitigate risk during cell culture process transfer 
Jochen Schaub, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany 
 
172 Use of the ambr 250 to enable rapid clone selection and process development for large 
scale manufacturing processes 
Colleen Clark, Bristol-Myers Squibb Company, USA 
 
173 Development and qualification of a scale-down model of a commercial mammalian cell 
culture bioreactor using Computational Fluid Dynamics 
Brianna Biscardi, Bristol-Myers Squibb Company, USA 
 
174 Step-wise strategy to address process characterization - Toward the definion of a 
standardized approach 
Claudia Berdugo, Catalent, USA 
 
175 Suspension culture of Pk15 cells for veterinary antigen production 
Ziomara P. Gerdtzen, University of Chile, Chile 
 
176 Development of a highly efficient and flexible media system for CHO fed-batch culture 
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